Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2025-04-25 Legal Proceedings Report
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a letter addressed to stock exchanges referencing Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015, which mandates disclosure of material events. The content focuses on updating the exchanges about pending litigation involving the company, including details of the litigation, the opposing party, forum, and financial implications. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory disclosure about legal proceedings, not a full legal proceedings report or financial report. This fits the category of Legal Proceedings Report (LTR), which covers updates on significant lawsuits or regulatory actions involving the company.
2025-04-25 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 95% confidence The document is a declaration under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, stating that no new encumbrance on shares has been made other than those already disclosed. It involves promoters and promoter groups making a formal declaration to stock exchanges and the audit committee. The content is regulatory in nature, related to shareholding disclosures, but it is not a report, financial statement, or announcement of voting results. It is a formal regulatory filing about share encumbrance status under SEBI rules. Given the nature and length of the document, it fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Major Shareholding Notification (MRQ) which typically involves changes in shareholding thresholds, or Director's Dealing (DIRS) which involves insider trades.
2025-04-15 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025. It is signed by the Company Secretary & Compliance Officer and encloses a certificate from the Registrar and Share Transfer Agent. The document length is only 1480 characters, indicating it is a brief regulatory filing rather than a full report. There is no financial data, management discussion, or detailed report content. It is not an annual or interim report, earnings release, or any other detailed financial or governance document. It is a compliance certificate submission, which fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document.
2025-04-05 English
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Legal Proceedings Report Classification · 95% confidence The document is a formal letter addressed to stock exchanges referencing Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events including litigation updates. The content includes detailed disclosures about ongoing litigation and regulatory orders involving the company, including references to the National Green Tribunal and the Supreme Court. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory disclosure about legal proceedings and litigation status, not a full audit report or annual/interim report. It is not a brief announcement but a detailed update on legal matters. Therefore, the document fits best under the category of Legal Proceedings Report (LTR).
2025-04-04 English
Disclosure under SEBI Takeover Regulations
Major Shareholding Notification Classification · 95% confidence The document is a declaration under regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011, stating no new encumbrance on shares other than those already disclosed. It involves promoters and promoter group entities making a formal declaration to stock exchanges and the audit committee. The content is a regulatory compliance declaration related to shareholding and encumbrance disclosures, not a financial report, audit report, or management information. It does not contain financial statements or detailed financial data. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes or declarations related to significant share ownership or encumbrances.
2025-04-04 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal communication from Nectar Lifesciences Ltd. addressed to stock exchanges, reporting the outcome of a Board Meeting held on April 1, 2025. It details the re-appointment of a Wholetime Director and the appointment of a new Company Secretary and Compliance Officer. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes disclosures as per SEBI circulars. The content focuses on changes in key managerial personnel and their profiles, which is typical of announcements related to board or management changes. There is no financial data, earnings information, or report publication mentioned. The document is not a full report but an announcement of board decisions regarding management appointments. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-04-01 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.